Cellectis (CLLS) Convertible Debt (2023 - 2024)
Cellectis (CLLS) recorded quarterly Convertible Debt of $138.6 million in Q4 2024, down 1.72% quarter-over-quarter from $141.0 million in Q3 2024, and up 2.54% on a YoY basis from $135.2 million in Q1 2024.
Cellectis (CLLS) Convertible Debt (2023 - 2024) Analysis & Trends
Cellectis' Convertible Debt history runs 2 years deep, the most recent figure standing at $138.6 million for Q4 2024.
- In Q4 2024, Convertible Debt rose 2.54% year-over-year to $138.6 million; the TTM figure through Dec 2024 stood at $138.6 million (up 2.54% YoY), while the FY2024 annual figure was $138.6 million, up 2.54% from the prior year.
- Convertible Debt was $138.6 million for Q4 2024 at Cellectis, down from $141.0 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $141.0 million in Q3 2024 to a low of $135.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 138.58 Mn |
| Sep 30, 2024 | 141.00 Mn |
| Jun 30, 2024 | 137.58 Mn |
| Dec 31, 2023 | 135.15 Mn |